MA54932A - Traitement contre le cancer - Google Patents

Traitement contre le cancer

Info

Publication number
MA54932A
MA54932A MA054932A MA54932A MA54932A MA 54932 A MA54932 A MA 54932A MA 054932 A MA054932 A MA 054932A MA 54932 A MA54932 A MA 54932A MA 54932 A MA54932 A MA 54932A
Authority
MA
Morocco
Prior art keywords
cancer treatment
cancer
treatment
Prior art date
Application number
MA054932A
Other languages
English (en)
Inventor
Anjali Narayan Avadhani
Porre Peter Marie Z De
Anne Elizabeth O'hagan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA54932A publication Critical patent/MA54932A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
MA054932A 2019-02-12 2020-02-11 Traitement contre le cancer MA54932A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19156806 2019-02-12
EP19176575 2019-05-24

Publications (1)

Publication Number Publication Date
MA54932A true MA54932A (fr) 2021-12-22

Family

ID=69467563

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054932A MA54932A (fr) 2019-02-12 2020-02-11 Traitement contre le cancer

Country Status (15)

Country Link
US (1) US20220168298A1 (fr)
EP (1) EP3923942A1 (fr)
JP (1) JP2022521173A (fr)
KR (1) KR20210126654A (fr)
CN (1) CN113423402A (fr)
AU (1) AU2020223467A1 (fr)
BR (1) BR112021015686A2 (fr)
CA (1) CA3126959A1 (fr)
IL (1) IL285466A (fr)
JO (1) JOP20210216A1 (fr)
MA (1) MA54932A (fr)
MX (1) MX2021009670A (fr)
SG (1) SG11202107850VA (fr)
TW (1) TW202045173A (fr)
WO (1) WO2020165181A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3201654A1 (fr) * 2020-12-11 2022-06-16 Erasca, Inc. Polytherapies pour le traitement du cancer
CN112957368A (zh) * 2021-04-02 2021-06-15 南昌大学 一种司维拉姆的新用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10208024B2 (en) * 2015-10-23 2019-02-19 Array Biopharma Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
JOP20190280A1 (ar) * 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية
PT3576740T (pt) * 2017-12-20 2023-08-18 Janssen Pharmaceutica Nv Tratamento de cancro

Also Published As

Publication number Publication date
US20220168298A1 (en) 2022-06-02
WO2020165181A1 (fr) 2020-08-20
CN113423402A (zh) 2021-09-21
JOP20210216A1 (ar) 2023-01-30
TW202045173A (zh) 2020-12-16
EP3923942A1 (fr) 2021-12-22
IL285466A (en) 2021-09-30
KR20210126654A (ko) 2021-10-20
SG11202107850VA (en) 2021-08-30
CA3126959A1 (fr) 2020-08-20
BR112021015686A2 (pt) 2021-10-26
MX2021009670A (es) 2021-09-08
JP2022521173A (ja) 2022-04-06
AU2020223467A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MA50056A (fr) Procédés de traitement de tumeur
MA49144A (fr) Polythérapies pour le traitement du cancer
KR20180084772A (ko) 암 치료를 위한 조합 치료법
MA47408A (fr) Traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA46361A (fr) Traitement du cancer de la prostate
MA52627A (fr) Traitement du cancer
KR102377742B1 (ko) 암치료약
GB201903546D0 (en) Cancer treatment
GB201820660D0 (en) Cancer treatments
MA53911A (fr) Polythérapie contre le cancer
IL287652A (en) Cancer treatment
GB201706451D0 (en) Cancer treatment
IL268463A (en) Cancer treatment
MA54932A (fr) Traitement contre le cancer
DK3407909T3 (da) Cancerbehandling
IL274626A (en) Cancer treatment
EP3576791A4 (fr) Traitement du cancer à médiation par calréticuline
IL288035A (en) Cancer treatment
GB201707864D0 (en) Platinum-reistant cancer treatment
KR20180084983A (ko) 암의 치료를 위한 피리미도-피리미다지논의 용도
KR20220035379A (ko) 암 치료를 위한 조합 요법
GB201819920D0 (en) Cancer treatment
GB201910644D0 (en) Cancer Treatment